Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations

Facultad de Biología, Centro de Estudios de Proteínas (CEP), Universidad de La Habana, Cuba.
Proteins Structure Function and Bioinformatics (Impact Factor: 2.92). 11/2008; 73(2):440-57. DOI: 10.1002/prot.22068
Source: PubMed

ABSTRACT Plasmepsins are aspartic proteases involved in the initial steps of the hemoglobin degradation pathway, a critical stage in the Plasmodium falciparum life cycle during human infection. Thus, they are attractive targets for novel therapeutic compounds to treat malaria, which remains one of the world's biggest health problems. The three-dimensional structures available for P. falciparum plasmepsins II and IV make structure-based drug design of antimalarial compounds that focus on inhibiting plasmepsins possible. However, the structural flexibility of the plasmepsin active site cavity combined with insufficient knowledge of the functional residues and of those determining the specificity of parasitic enzymes is a drawback when designing specific inhibitors. In this study, we have combined a sequence and structural analysis with molecular dynamics simulations to predict the functional residues in P. falciparum plasmepsins. The careful analysis of X-ray structures and 3D models carried out here suggests that residues Y17, V105, T108, L191, L242, Q275, and T298 are important for plasmepsin function. These seven amino acids are conserved across the malarial strains but not in human aspartic proteases. Residues V105 and T108 are localized in a flap of an interior pocket and they only establish contacts with a specific non-peptide achiral inhibitor. We also observed a rapid conformational change in the L3 region of plasmepsins that closes the active site of the enzyme, which explains earlier experimental findings. These results shed light on the role of V105 and T108 residues in plasmepsin specificities, and they should be useful in structure-based design of novel, selective inhibitors that may serve as antimalarial drugs.

Download full-text


Available from: Amaury Pupo, Jun 20, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Over the last decades, a vast structural knowledge has been gathered on the HIV-1 protease (PR). Noticeably, most of the studies focused the B-subtype, which has the highest prevalence in developed countries. Accordingly, currently available anti-HIV drugs target this subtype, with considerable benefits for the corresponding patients. However, in developing countries, there is a wide variety of HIV-1 subtypes carrying PR polymorphisms related to reduced drug susceptibility. The non-active site mutation, M36I, is the most frequent polymorphism, and is considered as a non-B subtype marker. Yet, the structural impact of this substitution on the PR structure and on the interaction with natural substrates remains poorly documented. Results Herein, we used molecular dynamics simulations to investigate the role of this polymorphism on the interaction of PR with six of its natural cleavage-sites substrates. Free energy analyses by MMPB/SA calculations showed an affinity decrease of M36I-PR for the majority of its substrates. The only exceptions were the RT-RH, with equivalent affinity, and the RH-IN, for which an increased affinity was found. Furthermore, molecular simulations suggest that, unlike other peptides, RH-IN induced larger structural fluctuations in the wild-type enzyme than in the M36I variant. Conclusions With multiple approaches and analyses we identified structural and dynamical determinants associated with the changes found in the binding affinity of the M36I variant. This mutation influences the flexibility of both PR and its complexed substrate. The observed impact of M36I, suggest that combination with other non-B subtype polymorphisms, could lead to major effects on the interaction with the 12 known cleavage sites, which should impact the virion maturation.
    BMC Genomics 10/2014; 15(S7):S5. DOI:10.1186/1471-2164-15-S7-S5 · 4.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Plasmepsin II (PlmII), an aspartic protease expressed in the food vacuole of Plasmodium falciparum (pf), cleaves the hemoglobin of the host during the erythrocytic stage of the parasite life cycle. Various peptidomimetic inhibitors of PlmII reported so far discriminate poorly between the drug target and aspartic proteases of the host organism, e.g., human cathepsinD (hCatD). hCatD is a protein digestion enzyme and signaling molecule involved in a variety of physiological processes; therefore, inhibition of hCatD by PlmII inhibitors may lead to pathophysiological conditions. In this study, binding of PlmII inhibitors has been modeled using the crystal structures of pfPlmII and hCatD complexes to gain insight into structural requirements underlying the target selectivity. A series of 26 inhibitors were modeled in the binding clefts of the pfPlmII and hCatD to establish QSAR models of the protease inhibition. In addition, 3D-QSAR pharmacophore models were generated for each enzyme. It was concluded that the contributions of the P(2) and P(3') residues to the inhibitor's binding affinity are responsible for the target selectivity. Based on these findings, new inhibitor candidates were designed with predicted inhibition constants K (pre)(i PlmII) reaching 0.2nm and selectivity index (S.I.)=K(pre)(i PlmII) >1200.
    Chemical Biology &amp Drug Design 11/2011; 79(4):411-30. DOI:10.1111/j.1747-0285.2011.01276.x · 2.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hemoglobin degradation pathway is the major source of nutrition of Plasmodium falciparum. Plasmepsin II is the key enzyme in hemoglobin degradation with two catalytic aspartates D34 and D214. The energy refined structure of Plasmepsin II of Plasmodium falciparum modeled by modeller 9v8 using PDB entry 1PFZ as template. Ligsitecsc program revealed three potential ligand binding sites where the pkt-364 is found to be more favorable containing critical aspartic residues (D34 and D214). Urea and its derivative, benzamide, are considered as seed molecules for de-novo generation of structurally complimentary lead molecules. LigbuilderV1.2 growing strategy was used for de-novo generation with 10 population cycles for each seed molecules. Binding energies were examined by Quantum3.3.0 for all the designed ligand molecules and the best molecules with -20KJ/mole and -18KJ/mole were found with some undesired activities. Iterative in-silico optimization of the examined molecules were done and finally de-novo generated N - [ (R) – hydroxy { [ 2 - ( 1 , 3 – oxathiol – 4 –yl ) phenyl ] amino } methyl ] acetamide and N - ( 2 – amino – 2 – oxoethyl ) – 3 - ( 1 - { [ 2 - ( methylamino ) ethyl ] (phenyl) amino } vinyl ) benzamide were found as the best fit over rule of 5 and other ADME parameters. Binding studies suggest the direct interaction of designed molecules with catalytic aspartates (D34 and D214) of Plasmepsin II having 2HB and 1 ionic bond and good number of VdW interactions. Thus, the designed molecules could possibly inhibit the action of PM II preventing the degradation of hemoglobin and thereby kill the parasite by starvation.
    International Journal of ChemTech Research 01/2011; 3(3):1538-1547.